Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

DYN

Dyne Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1818794Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income FY2025
$(446.0M)
EPS (Basic, as reported)
$-3.47
Net Margin FY2025
—
ROE FY2025
-45.9%
Total Equity
$972.0M
Shares Out
187M
Business description

Dyne Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itNet income: (15) → (446)
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Research & development(11)(45)(121)(143)(211)(281)(398)
General & administrative(3)(13)(29)(28)(31)(62)(70)
Total operating expenses(14)(59)(150)(171)(242)(344)(468)
Operating income(14)(59)(150)(171)(242)(344)(468)
Other income (expense), net(1)(1)1362622
Income tax expense————000
Net income(15)(59)(149)(168)(236)(317)(446)
EPS — basic——($2.93)($3.23)($3.95)($3.37)($3.47)
EPS — diluted——($2.93)($3.23)($3.95)($3.37)($3.47)

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.